CHMP opinions
AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences
The new site will expand research capabilities across immunology, neuroscience and oncology
Novartis presents positive results from two phase 3 trials for relapsing MS
Remibrutinib reduced relapse rates and improved disease progression rates
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo
The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy
In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will...
Shionogi to acquire IntraBio in deal worth $2bn
The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
Novartis announces trial results for remibrutinib in relapsing multiple sclerosis
MS affects nearly three million people worldwide and has three main types
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
EMA recommends granting marketing authorisation approval for Nezglyal
The treatment is for cerebral adrenoleukodystrophy, a rare neurodegenerative disease